<DOC>
	<DOCNO>NCT01487382</DOCNO>
	<brief_summary>This study conduct Japan . The aim study collect safety efficacy data use NovoRapid® ( insulin aspart ) child type 1 type 2 diabetes normal clinical practice condition .</brief_summary>
	<brief_title>Special Survey Paediatric Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<criteria>Requiring insulin therapy No treatment history NovoRapid® ( insulin aspart )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>